tiprankstipranks
Advertisement
Advertisement
Lumos Wins FDA CLIA Waiver for FebriDx, Unlocking US$1 Billion Market
PremiumCompany AnnouncementsLumos Wins FDA CLIA Waiver for FebriDx, Unlocking US$1 Billion Market
6d ago
Lumos Diagnostics Halts Trading Ahead of Key FDA FebriDx Update
Premium
Company Announcements
Lumos Diagnostics Halts Trading Ahead of Key FDA FebriDx Update
8d ago
Lumos Diagnostics Seeks ASX Quotation for Additional Shares
Premium
Company Announcements
Lumos Diagnostics Seeks ASX Quotation for Additional Shares
28d ago
Lumos Hits Paediatric Trial Milestone, Unlocks BARDA Funding for FebriDx Expansion
PremiumCompany AnnouncementsLumos Hits Paediatric Trial Milestone, Unlocks BARDA Funding for FebriDx Expansion
1M ago
Lumos Diagnostics Issues New Shares on Employee Option Exercises, Affirms Compliance Ahead of Half-Year Report
Premium
Company Announcements
Lumos Diagnostics Issues New Shares on Employee Option Exercises, Affirms Compliance Ahead of Half-Year Report
2M ago
Lumos Diagnostics Seeks Quotation of Additional 768,159 Shares on ASX
Premium
Company Announcements
Lumos Diagnostics Seeks Quotation of Additional 768,159 Shares on ASX
2M ago
Lumos Diagnostics Seeks ASX Quotation for 5.2 Million New Shares
PremiumCompany AnnouncementsLumos Diagnostics Seeks ASX Quotation for 5.2 Million New Shares
3M ago
Lumos Diagnostics Showcases FebriDx in Investor Webinar on Reducing Diagnostic Uncertainty
Premium
Company Announcements
Lumos Diagnostics Showcases FebriDx in Investor Webinar on Reducing Diagnostic Uncertainty
3M ago
Lumos Diagnostics Expands FebriDx® Distribution to the Baltic Region
Premium
Company Announcements
Lumos Diagnostics Expands FebriDx® Distribution to the Baltic Region
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100